Jubilant Pharmova Limited

BSE:530019 Stock Report

Market Cap: ₹168.3b

Jubilant Pharmova Past Earnings Performance

Past criteria checks 1/6

Jubilant Pharmova's earnings have been declining at an average annual rate of -30.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 6.3% per year. Jubilant Pharmova's return on equity is 9.9%, and it has net margins of 8.6%.

Key information

-30.1%

Earnings growth rate

-30.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-6.3%
Return on equity9.9%
Net Margin8.6%
Next Earnings Update31 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jubilant Pharmova makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:530019 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2469,1975,93123,2500
30 Jun 2468,4775,52822,2120
31 Mar 2467,02977122,8730
31 Dec 2366,22337822,4440
30 Sep 2364,977-44622,3080
30 Jun 2364,169-1,01721,8450
31 Mar 2362,817-61022,1510
31 Dec 2261,31396421,7260
30 Sep 2258,8931,63121,2920
30 Jun 2259,4723,00420,7340
31 Mar 2261,3024,13920,7390
31 Dec 2161,8245,27320,3000
30 Sep 2166,4326,95319,8750
30 Jun 2165,7716,99319,4480
31 Mar 2160,9855,74119,4400
31 Dec 2092,6598,33922,6830
30 Sep 2089,7447,75922,5270
30 Jun 2088,6558,01322,1660
31 Mar 2059,7586,77818,8430
31 Dec 1991,4865,38521,4510
30 Sep 1992,1055,95921,0610
30 Jun 1992,1405,56919,7850
31 Mar 1991,1085,74520,0930
31 Dec 1889,7728,28619,4580
30 Sep 1886,6797,80318,6910
30 Jun 1880,4026,98216,9710
31 Mar 1875,1786,42816,1870
31 Dec 1768,6416,38114,7480
30 Sep 1762,5455,44913,6100
30 Jun 1759,9825,61312,4540
31 Mar 1758,6145,75712,7920
31 Dec 1658,0134,76312,3820
30 Sep 1657,0974,79512,1070
30 Jun 1657,7624,61211,9290
31 Mar 1657,4913,91811,6740
31 Dec 1558,3764,03516,0330
30 Sep 1559,0362,75415,9180
30 Jun 1558,11765515,7790
31 Mar 1558,262-57811,2840
31 Dec 1458,863-1714,5430
30 Sep 1458,8371,52914,6360
30 Jun 1458,6411,66411,2130
31 Mar 1458,0341,09014,9570
31 Dec 1355,983-20713,8000

Quality Earnings: 530019 has a large one-off gain of ₹2.1B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 530019 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 530019's earnings have declined by 30.1% per year over the past 5 years.

Accelerating Growth: 530019 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 530019 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).

Return on Equity

High ROE: 530019's Return on Equity (9.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:17
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jubilant Pharmova Limited is covered by 31 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harith AhamedAvendus Spark
Deepak KhetanAxis Capital Limited
Gaurav ChughBatlivala & Karani Securities India Pvt. Ltd.